PEBP1 and triple-A syndrome: To further verify the impact of these biomimetic nanovesicles loaded with PEBP1 mRNA on AAA in vivo, we established an in situ model of AAA in mice and applied biomimetic nanovesicles for treatment, achieving a significant therapeutic effect.